April 2016

GRAND RAPIDS, Mich. (WOOD) — A big development in the treatment of epilepsy in children is about to get underway on Grand Rapids’ Medical Mile. Helen Devos Children’s Hospital is in the final stages of approval to start testing cannabidiol oil in children who suffer from neurological disorders like epilepsy, 24 Hour News 8 has […]

by

Insys Therapeutics, Inc. (NASDAQ:INSY) Q1 2016 Earnings Conference Call April 28, 2016 10:00 AM ET Executives Ilanit Allen – Investor Relations John Kapoor – Chairman, President and Chief Executive Officer Darryl Baker – Chief Financial Officer Santosh Vetticaden – Chief Medical Officer Analysts Randall Stanicky – RBC Capital Markets David Amsellem – Piper Jaffray Co. […]

by

LONDON, April 28, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 May, 2016 its second quarter and half-year financial results for the period ending 31 March, 2016. GW will […]

by

This article is sponsored by PlusCBD Oil, a product line from CV Sciences (formerly CannaVest). CV Sciences is one of the leading suppliers and manufacturers of agricultural hemp-derived CBD bulk and finished products. Phytocannabinoids like cannabidiol (CBD) are a subclass of cannabinoids derived from plants, typically hemp. In the 1800s, hemp plants were widely cultivated […]

by

The United States Drug Enforcement Administration (DEA) has given formal approval to a controlled clinical trial to study the effectiveness of whole-plant cannabis as a treatment for post-traumatic stress disorder (PTSD) in military veterans, the California-based non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced last week. Post-traumatic stress disorder is an anxiety disorder that impacts an estimated eight […]

by

The FDA designates GW Pharmaceuticals’ (GWPH -0.9%) Epidiolex (cannabidiol) an Orphan Drug for the treatment of Tuberous Sclerosis Complex (TSC), a rare genetic condition characterized by the formation of non-malignant tumors in different organs that frequently cause seizures. Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, […]

by

FORTUNE – The unofficial pot-smoking holiday of April 20 may be over, but marijuana advocates got another reason to celebrate on Thursday. The U.S. Drug Enforcement Administration for the first time approved smoking marijuana as legitimate medical research. The DEA green-lit a clinical trial of smoked marijuana for the treatment of post-traumatic stress disorder (PTSD) […]

by

The U.S. Drug Enforcement Agency agreed for the first time ever this week to let researchers conduct clinical trials with marijuana to examine the potential benefits of using the plant to treat post-traumatic stress disorder. A California-based nonprofit research group, the Multidisciplinary Approach to Psychedelic Studies (MAPS), announced on Thursday that the DEA will allow […]

by

The DEA appears to have reversed its staunch opposition to smoking marijuana. The regulator has, for the first time ever, approved smoking marijuana as legitimate medical research, which might make it easy for medical practitioners to prescribe smoking weed as a line of treatment. Currently, the trial is restricted to PTSD, but if the results […]

by

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). TSC is a rare genetic disorder, the most common symptom […]

by